Access

Technical Report


Nature Medicine 13, 1382 - 1387 (2007)
Published online: 28 October 2007 | Corrected online: 12 November 2007 | doi:10.1038/nm1650



There is an Erratum (December 2007) associated with this Technical Report.

Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy

Sam E Day1,5, Mikko I Kettunen1,5, Ferdia A Gallagher1,2, De-En Hu1, Mathilde Lerche3, Jan Wolber4, Klaes Golman3, Jan Henrik Ardenkjaer-Larsen4 & Kevin M Brindle1


Measurements of early tumor responses to therapy have been shown, in some cases, to predict treatment outcome. We show in lymphoma-bearing mice injected intravenously with hyperpolarized [1-13C]pyruvate that the lactate dehydrogenase–catalyzed flux of 13C label between the carboxyl groups of pyruvate and lactate in the tumor can be measured using 13C magnetic resonance spectroscopy and spectroscopic imaging, and that this flux is inhibited within 24 h of chemotherapy. The reduction in the measured flux after drug treatment and the induction of tumor cell death can be explained by loss of the coenzyme NAD(H) and decreases in concentrations of lactate and enzyme in the tumors. The technique could provide a new way to assess tumor responses to treatment in the clinic.


MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.